Familial eosinophilia: a benign disorder?

Area of Science:

• Immunology
• Genetics
• Hematology

Background:

• Familial eosinophilia (FE) is an autosomal dominant disorder.
• FE is characterized by marked eosinophilia, with variable progression to end-organ damage.
• The pathogenesis and clinical distinction from hypereosinophilic syndrome (HES) require further definition.

Purpose of the Study:

• To define the pathogenesis of familial eosinophilia.
• To compare clinical and laboratory findings in familial eosinophilia versus unaffected family members.
• To differentiate familial eosinophilia from nonfamilial hypereosinophilic syndrome.

Main Methods:

• Detailed clinical evaluation of 13 affected and 11 unaffected family members at the National Institutes of Health (NIH).
• Assessment of eosinophil morphology via light and transmission electron microscopy.
• Flow cytometry to analyze eosinophil activation markers (CD69, CD25, HLA-DR) and measurement of eosinophil granule proteins (EDN, MBP).

Main Results:

• No clinical abnormalities were more frequent in individuals with FE compared to unaffected family members.
• A decreased prevalence of asthma was observed in individuals with FE.
• Eosinophils in FE showed elevated EDN and MBP levels, and increased expression of activation markers compared to controls, but lower than in HES.
• Eosinophil morphology was normal in both FE and control groups.

Conclusions:

• Familial eosinophilia is distinguished from HES by a more benign clinical course.
• The relative lack of eosinophil activation may contribute to the milder phenotype observed in FE.
• FE does not appear to be associated with significant clinical abnormalities beyond eosinophilia itself.